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Abstract
Background: Chemotherapy is the only therapy option for the majority of AML patients, however, there are several
limitations for this treatment. Our aim was to find a new chemotherapy strategy that is more effective and less
toxic.
Methods: MTT assays and a xenograft mouse model were employed to evaluate the synergistic activity of all-trans
retinoic acid (ATRA) combined with topotecan (TPT). Drug-induced DNA damage and apoptosis were determined
by flow cytometry analysis with PI and DAPI staining, the comet assay and Western blots. Short hairpin RNA
(shRNA) and a RARα plasmid were used to determine whether RARα expression influenced DNA damage and
apoptosis.
Results: We found that ATRA exhibited synergistic activity in combination with Topotecan in AML cells, and the
enhanced apoptosis induced by Topotecan plus ATRA resulted from caspase pathway activation. Mechanistically,
ATRA dramatically down regulated RARα protein levels and led to more DNA damage and ultimately resulted in
the synergism of these two agents. In addition, the increased antitumor efficacy of Topotecan combined with ATRA
was further validated in the HL60 xenograft mouse model.
Conclusions: Our data demonstrated, for the first time, that the combination of TPT and ATRA showed potential
benefits in AML, providing a novel insight into clinical treatment strategies.
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Background
Acute myeloid leukemia (AML) is the most common
acute leukemia worldwide and has high mortality rates,
the overall median survival for patients with AML is
6.5 months due to limited treatment choices [1, 2]. The
current treatment options for patients with AML are
bone marrow transplants, radiofrequency ablation and
chemotherapy [3]. Bone marrow transplants are only
curative for a small percentage of matching patients [4].
Meanwhile, the efficacy or response rate of radiofre-
quency ablation in advanced AML is pretty low [5].
Chemotherapy, the only or necessary choice for most
AML patients, is often limited by toxicities [6]. There-
fore, it is critical to discover effective drug treatments
for AML patients.
Topotecan [10-hydroxy-9-dimethylaminomethyl-(S)-
camptothecin] (TPT), a semisynthetic topoisomerase 1
inhibitor derived from camptothecin (CPT), is active in
patients with different types of solid tumors [7–10]. TPT
forms a covalent complex between Topoisomerase 1 and
DNA, also called the cleavage complex, resulting in
DNA damage during cell replication and transcription,
ultimately leading to apoptosis [11, 12]. This mechanism
is being investigated for salvage and front-line therapy in
AML patients combined with other medicines, such as
etoposide, cytarabine, and cyclophosphamide [13–17].
Unfortunately, clinical studies have shown that the
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activity of these therapies in AML is also limited due to
their dose-dependent toxicity. Therefore, discovering po-
tential drugs synergistic to the anticancer activity of
TPT that do not enhance its toxicity is critical.
All-trans retinoic acid (ATRA) is a derivative of
vitamin A that has good efficacy and has shown less side
effects in APL during clinical observations [18]. Experi-
mental studies showed that ATRA treatment in AML af-
fects leukemic cell morphology, regulation of cell cycle
progression and apoptosis by activating nuclear receptors,
including retinoic acid receptors (RAR types α, β, γ) and
retinoid X receptors (RXR types α, β, γ) [19]. Therefore,
ATRA is the most promising agent to enhance the antitu-
mor activity of TPT in AML.
In this study, we identified that the combination of
TPT with ATRA have synergistic effects to AML in vitro
and in vivo. Our study provides molecular insights for
apoptosis involving TPT and ATRA by demonstrating
that ATRA helps TPT cause serious DNA damage leading
the AML cells HL60 to apoptosis, and RARα is involved
in this process. Our results indicate that the TPT-ATRA
combination may be a promising alternative chemothera-
peutic strategy for AML.
Methods
Reagents
ATRA (cat # R2625) was obtained from Sigma (St Louis,
MO, USA) and stored in ethanol at −40 °C. TPT, with
more than 99 % purity, is synthesized by professor Wei
Lu (East China Normal University) and dissolved in
dimethylsulfoxide (DMSO) as stock solution at 10 mM.
The stock solution was kept frozen in aliquot at −40 °C
and thawed immediately prior to each experiment.
Cell line and cell culture
HL60, NB4 and U937, the human acute myelocytic
leukemia cell lines, were obtained from ATCC, and they
were maintained in complete media (RPMI-1640 medium
(Gibco, Grand Island, NY, USA) supplemented with 10 %
heat-inactivated fetal bovine serum (FBS) plus penicillin
(100 units/ml) and streptomycin (100 ug/ml)) at 37 °C in
5 % CO2.
Cell Proliferation assay in vitro
The cytotoxic activity was detected by MTT assay. After
Cells were cultured in 96-well plates at 4 × 103 cells/well,
and allowed to proliferate to confluence in 5 % CO2 in-
cubator at 37 °C overnight; exposed to different concen-
trations of TPT, ATRA or TPT combined with ATRA
for 48 h. Cells were then incubated with MTT 5 mg/ml
(Sigma, USA) for 4 h. A quantity of 100 ml of DMSO
(dimethyl sulfoxide) was added to each well after re-
moving the supernatant. Cell viability was obtained by
measuring the absorbance on a Multiskan Spectrum
(Thermo Electron Corporation, Marietta, Ohio) at
570 nm.
The growth inhibition was calculated according to
the following formula: the Growth Inhibition Ratio
(IR%) = [(the absorbance of blank control group – the
absorbance of experimental group)/the absorbance of
blank control group] × 100 %.
PI staining for flow cytometry
The sub-G1 analysis after PI staining was employed to as-
sess the apoptosis. HL60 cells (105/ml) were seeded into 6-
well plates and exposed to either or both of TPT and
ATRA for 48 h. Cells were then harvested and washed with
ice-cold PBS, fixed with precooled 75 % ethanol at −20 °C
overnight. Cells were washed, and resuspended in 500 μl of
PBS containing 100 μg/ml RNase (Amersco, Solon, OH,
USA), then incubated at 37 °C for 30 min. After incuba-
tion, the cells were stained with 200 μg/ml propidium iod-
ide (PI, Sigma, St Louis, MO, USA) in the dark at room
temperature for 30 min. For each sample, at least 2 × 104
cells should be analyzed using an FACS-Calibur cytometer
(BD Biosciences, Sanjose, CA), and the data were analyzed
using cellquest software (BD biosciences).
JC-1 stain for mitochondrial membrane potential (△Ψm)
HL60 cells were inoculated into 6-well plates (150,000/
well) for 24 h growth. After stabilisation for 24 h HL60
were treated with TPT, ATRA or both for 24 h and then
harvested. Wash twice with PBS and suspend in 500 μl
PBS with 2.5 μl JC-1 (20 μg/ml). Keep the samples in
37 °C, 5 % CO2, for 30 min. Then analyze immediatly
with the flow cytometer, typically equipped with a
488 nm argon laser. JC-1 is a cationic dye that exhibits
potential-dependent accumulation in mitochondria, indi-
cated by a fluorescence emission shift from green (525 ±
10 nm) to red (610 ± 10 nm). Samples (1 × 104 cells/sam-
ple) were analyzed by FACS Calibur (Becton Dickinson,
CA, USA).
Immunofluorescence
For morphological studies, exponentially growing cells
were cultured in 3 × 105/well in 6-well plates and treated
with TPT, ATRA or both for 48 h. The cells were
washed with PBS, fixed with 0.1 % Triton X-100 for
15 min at room temperature, stained with 4’,6-dianidino-
2-phenylindole dihydrochloride (DAPI, 2.0 μg/ml,
Sigma) for another 15 min. Morphological changes of
cell nucleus were examined in a fluorescence micro-
scope, and they were photographed using a digital color
camera DFC 300 FX (Leica, Wetzlar, Germany).
Western blot analysis
The protein samples were prepared as described previ-
ously. Briefly, proteins of HL60 cells were extracted in
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lysis buffer (150.0 mM NaCl, 50 mM Tris–HCl, 1 mM
EDTA, 0.1 % SDS, 0.5 % dexoycholic acid, 0.02 % sodium
azide, 1 % NP-40, 2.0 μg/ml aprotinin, 1 mM phenyl-
methylsulfonylfluoride). The lysates were centrifuged at
104 × g for 15 min at 4 °C. Equivalent amounts of proteins
were analyzed by 8 %-15 % SDS-PAGE and electroblotted
onto PVDF membranes (Millipore Corporation, Billerica,
Massachusetts), and probed with primary antibodies. Ap-
propriate antibodies to anti-caspase-3, anti-poly-ADP-ri-
bose polymerase (PARP), anti-Bax, anti-chk1, anti-chk2
and anti-β-actin from Santa Cruz Biotechnology (Santa
Cruz, CA, USA); anti-Bcl-2, anti-p-chk1, anti-p-chk2, and
anti-γ-H2AX from Cell Signaling Technology (Beverly,
MA, USA); and anti-Cytochrome C from Cell Signaling
Technology (Boston, MA, USA) were used. The proteins
were visualized with peroxidase-coupled secondary anti-
bodies (Southern Biotech, Birmingham, UK), and using the
enhanced chemiluminescence detection system (Biological
Industries, Beit Haemek, Israel) for detection.
Alkaline comet assay
The alkaline comet assay, also called alkaline single-cell
gel electrophoresis assay, was done according to the pro-
cedure of Huang et al. [20]. with minor modification.
Briefly, drug-treated HL60 cells (105/ml) were pelleted
and resuspended in ice-cold PBS. A 50 μl sample of re-
suspended cells was the mixed with an equal volume of
prewarmed 1 % low-melting point agarose. The cell-
agarose mixture was placed on a slide precoated with
0.5 % agarose and spread gently with a coverslip. After
10 min at 4 °C, immersed the slides in precooled lysis
buffer [2.5 M NaCl, 100 mM Na2EDTA, and 10 mM
Tris–HCl (pH 10)] for 90 min in the dark. After soaking
with electrophoresis buffer (0.3 M NaOH and 1 mM
EDTA) for 20 min, the slides were subjected to electro-
phoresis for 15 min. The cells were stained with DAPI at
last, and individual cells were observed in a fluorescence
microscope, and photographed by DFC 300 FX (Leica,
Wetzlar, Germany).
Retroviral infection
To prepare the retroviruses, 293FT cells were plated at
6–8 × 105 cells per well in 6-well plates coated with
20 μg ml−1 of poly-ornithine. Twenty-four hours after
plating, the cells were transfected with RARα shRNA
plasmid, along with pUMVC and pCMV-VSV-G plas-
mids at the ratio of 2.125 μg of plasmid DNA to 5 μl of
Lipofectamine 2000 in 500 μl Opti-MEM (both from
Invitrogen). The ratio of shRNA:Pumvc: pCMV-VSV-G
was 8:8:1. Twenty-four hours after transfection, the
DMEM media was replaced with fibroblast (MEME)
media. The next day the culture media containing the
retroviruses was harvested and mixed 1:1 with 0.6 μg ml−1
polybrene (Sigma-Aldrich). The cell debris in the mixtures
was removed using 0.45 μm low-protein-binding filters
(Nalgene). The HL60 cells were plated at 2.5 × 105 cells
per well in 6-well plates one day before infection with the
retroviruses. The retrovirus solution was mixed with the
cells for 6 h, then certain amount of fresh 1640 media was
added for reducing the toxcity of polybrene. After in-
fection of 24 h, cells were immediately transferred to
complete RPMI-1640 supplemented with 10 % fetal bo-
vine serum and cultured at 37 °C until analysis.
Lentivirus transduction
With Lipofectamine 2000, vesicular stomatitis virus-
pseudo-typed vectors were produced by transient
cotransfection of 293FT cells with 10 μg of the expres-
sion construct (pccl, or pccl-RARa), 10 μg of the pR△8.9
packaging plasmid, and 2 μg of the pMD.G envelope
plasmid. Sodium pyruvate (Invitrogen) induction was
performed according to the manufacturer’s instructions.
After 72 h, the viral supernatants were harvested, centri-
fuged (800 g, 15 min), and filtered. After determination
of the titer of the vector supernatants, HL60 cells were
transduced with the indicated lentivirus particles (multi-
plicity of infection of 1 : 1) in the presence of 8 μgmL−1
polybrene. A second cycle of transduction was per-
formed 24 h later with new viral supernatants in the
presence of fresh polybrene. After 24 h, the cells were
washed and cultured in fresh medium.
Animals and antitumor activity in vivo
Male immune-deficient nude mice at 4 weeks of age
(National Rodent Laboratory Animal Resource, Shanghai
Branch, China) were maintained in pathogen-free condi-
tions with irradiated chow. Animals were unilaterally,
subcutaneously (s.c.) injected with 5 × 106 HL60 cells/
tumor in 0.1 ml Matrigel (Collaborative Biomedical
Products, Bedford, MA). When HL60 cells formed palp-
able tumors, mice were divided randomly into 4 groups
receiving control (n = 3), TPT alone (n = 3), ATRA alone
(n = 3) or combination of both TPT and ATRA (n = 3).
ATRA (5 mg/kg) was dissolved in corn oil and given to
mice by gavage and TPT (2 mg/kg) was given to mice by
intraperitoneal injection every two days of the experi-
mental period. Control group received vehicle (0.5 %
methylcellulose, 0.2 % Tween 80 and 99.3 % DDW, i.g.
administration) everyday and 0.9 % saline solution by in-
traperitoneal injection every two days of the experimen-
tal period. Body weight and tumors were measured
every two days. Tumor sizes were calculated by the for-
mula: (length × width × width)/2, and the length, width
and height is in millimeters. At the end of the experi-
ment, animals were sacrificed by CO2 asphyxiation and
tumor weights were measured after their careful resec-
tion. Tumor tissue was collected for analysis. The indi-
vidual relative tumor volume (RTV) was calculated
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according to the following formula: RTV = VN/V0, where
VN is the tumor volume on day n and V0 is the tumor
volume on day of initial treatment. Therapeutic effects
of treatment were expressed in terms of T/C% using the
calculation formula T/C (%) = mean RTV of the treated
group/mean RTV of the control group × 100 % [21].
All procedures were in accordance with the ethical
standards of, and the protocols were approved by, the
Animal Ethical and Welfare Committee (AEWC), Center
for Drug Safety Evaluation and Research, Zhejiang
University.
TUNEL assay
To evaluate the apoptotic response in tumor tissue, we
applied terminal deoxynucleotidyl transferase (TdT)-me-
diated dUTP-digoxigenin nick-end labeling (TUNEL)
technique, to formalin-fixed tumor samples in paraffin
blocks, using the one-step TUNEL apoptosis assay kit
produced by Beyotime Institute of Biotechnology in
China. The sections (4–5 μm) mounted on glass slides
were deparaffinized, rehydrated thoursough graded alco-
hols to water, treated with 20 μg/ml proteinase K (37 °C,
20 min) and then washed in 1 × Tris buffer. TUNEL
assay was then performed according to the manufac-
turer’s instructions.
Statistical analysis
Data were presented as mean ± SD for thoursee separate
experiments. Comparions between groups were made
with unpaired Student’s two-tailed t test and P < 0.05
was considered statistically significant.
Results
TPT and ATRA synergistically induce a cytotoxic effect in
AML cells
To evaluate the potential synergy between ATRA and
the Topoisomerase1 inhibitor TPT, cells (HL60, NB4
and U937) were exposed for 48 h to increasing concen-
trations of TPT (0, 20, 40, 60, 80 nM) alone or in com-
bination with ATRA at a concentration that reduces cell
viability according to data from preclinical research and
our laboratory. As shown in Fig. 1b, a synergistic effect
was observed in ATRA combined with lower concentra-
tions of TPT (20 nM and 40 nM). However, as the con-
centration of TPT increased the cytotoxicity appeared
much more severe with no significant differences be-
tween the TPT group (60 nM and 80 nM) and the TPT
plus ATRA group. To validate the combination effi-
ciency, we calculated the Coefficient of Drug Interaction
(CDI) values, which are used to quantify drug synergism.
CDI values less than, equal to or greater than 1 indicate
that the drugs are synergistic, additive or antagonistic,
respectively. CDI values less than 0.7 indicate that the
drugs are significantly synergistic. The CDI values for
different ratio concentrations of ATRA and TPT were
calculated. As shown in Fig. 1c, the combination of
ATRA and TPT had apparent synergism in HL60, NB4
and U937 cells with CI values <1. Cells treated with the
combination of TPT and ATRA showed cell morphology
changes and had more cell debris appearing compared
to TPT or ATRA groups in Fig. 1d. Thus, we demon-
strated that ATRA has synergistic cytotoxicity with TPT
in AML cells.
ATRA enhances TPT–triggered caspase-dependent
apoptosis in vitro
To further explore the mechanisms of enhanced antitu-
mor activity caused by the combination of TPT and
ATRA, we examined their effects on apoptosis and cas-
pase signaling pathways. Flow cytometry analysis after PI
staining was used first to identify the apoptosis-inducing
effects. As shown in Fig. 2a, PI staining for sub-G1 con-
tent analysis was used to characterize the apoptosis
process in HL60 cells treated with TPT (20 nM and
40 nM), 1 μM ATRA or the combination for 48 h. Ex-
posure to ATRA drove a few cells to apoptosis, and the
content of sub-G1 was close to the control group (ap-
proximately 2 %). However, using ATRA with TPT gen-
erated more apoptotic cells compared to TPT treatment
alone. Then, DAPI staining further showed that the
combination of 1 μM ATRA and TPT for 48 h triggered
more apoptosis compared to the treatment of either
drug alone. As Fig. 2c depicts, apoptotic bodies were
seldom found in control cells and the monotreated
ATRA cells. However, apoptotic bodies appeared in cells
exposed to TPT. Adding ATRA showed more apoptotic
bodies with the accompanied nuclei shrinking and
disintegrating.
To explore the signaling mechanism for TPT and
ATRA synergistic induction of apoptosis, we investigated
the expression levels of apoptosis-related proteins, such
as caspase-3 and PARP, as shown in Fig. 2d, using West-
ern blot analysis. Incubation with TPT at the indicated
concentrations (20 nM and 40 nM) combined with
ATRA (1 μM) for 24 h caused significant cleavage of
PARP compared to the monotreated cells. Pro-caspase-
3, upstream PARP [22], was cleaved more severely with
the combination of 40 nM TPT and ATRA. Then, we
used Z-VAD-FMK, the pan-caspase inhibitor, to further
confirm the mechanism previously mentioned. As shown
in Fig. 2e, the apoptosis induced by the combination
treatment was almost reversed in the presence of Z-
VAD-FMK, as detected by the PI (sub-G1) staining
assay. All of these results indicated that caspase involve-
ment led to apoptosis triggered by TPT plus ATRA. In
summary, our results demonstrated that a combination
treatment of TPT and ATRA triggers apoptosis via caspase
cascades leading to increased cell death.
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Mitochondrial damage was involved in caspase-dependent
apoptosis
Mitochondrial damage in response to cellular conditions
is an important constituent of apoptosis, and the mito-
chondrial membrane potential is one of the most re-
markable events [23]. In order to explore the role of
mitochondrial damage in apoptosis induced by a com-
bination treatment of TPT and ATRA, JC-1 staining and
flow cytometry were conducted after a 24 h treatment.
The results showed that cells treated with the combined
TPT and ATRA induced the loss of mitochondrial
membrane potential compared to TPT or ATRA
groups in Fig. 3a-b. The oncoprotein Bcl-2 is an antag-
onist of the mitochondrial pathway for apoptosis [24].
BAX is a member of the Bcl-2 gene family that forms a
heterodimer with bcl-2 and functions as an apoptotic
activator [25]. As shown in Fig. 3c, Western blot
analysis revealed that bcl-2 is down-regulated and bax
is up-regulated in HL60 cells treated with TPT and
ATRA together. Cytochrome C, which normally
Fig. 1 Combinational cytotoxicity of Topotecan (TPT) and ATRA. a Chemical structures of TPT and ATRA. b Combination of TPT and ATRA induce
cytotoxicity in HL60, NB4 and U937 cells. 4 × 103 cells per well were cultured in 96-well plates and incubated with the indicated concentrations
of TPT and ATRA for 48 h. Mean ± SD from three independent experiments. *: Compared to TPT group, p < 0.05. c CDI values at different ratio
concentrations of TPT and ATRA (1 or 2 μM) were calculated by the proliferation inhibition rates. Each study was performed three times and the
error bars represent the SD around the mean. d Cell morphology change was observed by microscope (magnification 200×) after combination of
TPT and ATRA
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resides exclusively in the intermembrane space of
mitochondria, is released into the cytosol during apop-
tosis. Cytochrome C release from mitochondria to the
cytoplasm was shown to be up-regulated in HL60 cells
treated with TPT and ATRA together, as depicted in
Fig. 3c. These data suggest that the combination
treatment of TPT and ATRA induced mitochondrial
associated-apoptosis.
Fig. 2 Combination of TPT and ATRA induce apoptosis in HL60 cells. a and b Effects of ATRA in combination with TPT and ATRA on cell cycle
kinetics of HL60 cells. Cell cycle analysis was done after propidium iodide (PI) staining on cells exposed to TPT or ATRA either alone or in
combination as indicated. *: Compared to 40 nM TPT group, p < 0.05. c Morphology of apoptotic bodies in HL60 cells treated with TPT, ATRA, or
combination for 48 h. Cells were stained with DAPI and observed by fluorescence microscope (magnification 200×). d HL60 cells were exposed
to TPT, ATRA, or combination for 24 h, after which, protein extracts were immunoblotted with specified antibodies for PARP and cleaved-caspase-3.
e. HL60 cells were pretreated with 25 μM Z-VAD-FMK (the pan-caspase inhibitor) for 1 h and treated with TPT and/or ATRA for 24 h. The cells were
analysed on flow cytometry. *: Compared to ethanol group, p < 0.05. The experiments were performed three times independently, and the error bars
represent the SD around the mean
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Induction of apoptosis mediated by the combined
treatment of TPT and ATRA is correlated to enhanced
DNA damage in AML cells
TPT is a cytotoxic drug that adheres Topoisomerase 1
to DNA, which inhibits the function of Topoisomerase 1
in DNA repair [12]. Trapped Topoisomerase 1 leads to
single strand DNA breakage and then to cell death. We
used the comet assay to determine if ATRA plays a role
in TPT induced-DNA damage. The alkaline version
detects both single-strand and double-strand breaks
(DSBs), and the neutral version only detects double-
strand breaks [26, 27]. Exposure to different concentra-
tions of TPT and ATRA for one hour showed obvious
“comet tails” in two of the groups: the combination
group and the positive control group for 200 nM TPT.
The other groups showed only obscure “halos” without
clear directions (Fig. 4a). The results demonstrated that
treatment with ATRA and TPT for one hour induced
HL60 DNA damage with 200 nM TPT. However, neither
treatments of 1 μM ATRA or 40 nM TPT had similar
effects.
Because the “tails” were caused by single-strand or
double-strand breaks, we next detected the level of
phosphorylated-H2AX (γ-H2AX) in DNA DBSs that are
accompanied by the elevation of γ-H2AX. Phosphoryl-
ation of histone H2AX on serine 139 was one of the
earliest cellular responses after the formation of DNA
damage [28]. This phosphorylated form of H2AX (re-
ferred to as γ-H2AX) was used as a marker for the pres-
ence of DNA damages. AML cells, including HL60, NB4
and U937 cells, were incubated with TPT, ATRA, or
both and proteins were collected at 1, 3, 6, and 8 h, re-
spectively. As shown in Fig. 4b, γ-H2AX expression in-
creased from a very low level to a high level, which
demonstrated that only exposure to TPT and ATRA for
eight hours induced DBSs. Therefore, the “comet tails”
formed after one hour of drug treatment were caused by
SSBs (Fig. 4c). TPT inhibits topoisomerase1 and causes
single-strand DNA breaks, which inhibit DNA function
and ultimately lead to cell death by generating double-
stranded DNA breaks during DNA replication [29]. Fur-
thermore, we examined p-Chk1 and p-Chk2 which are
Fig. 3 Mitochondrial damage was involved in caspase-dependent apoptosis. a and b Effects of TPT, ATRA, or combination for 24 h on loss of
mitochondrial membrane potential in HL60 cells were detected by flow cytometry after JC-1 staining. b The rates of red to green after HL60 Cells
treated with TPT, ATRA, or combination for 24 h. c Effects of TPT, ATRA, or combination on Bcl-2, Bax and Cytochrome C protein expression were
analyzed by western blot
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essential for responses to DNA damage [30]. These two
checkpoint kinases were improved with the combination
treatment of TPT and ATRA (Fig. 4d). These results in-
dicated that ATRA and TPT synergistically induced
apoptosis by causing serious DNA damage.
RARα was involved in TPT-induced DNA damage
RARα, the main target of ATRA, plays an important role
in ATRA-therapies. Previous data has shown that ATRA
elevates the activity of proteasomes leading to RARα
protein degradation by the ubiquitin-proteasome path-
way [31, 32]. We found similar results for the ATRA
treatment with prolonged time (Fig. 5a). Interestingly,
the combination of ATRA and TPT downregulates
RARα. To explore the role of RARα in this combination
therapy, retroviral shRNA was used to knockdown the
RARα expression levels in HL60 cells (Fig. 5b). Two days
later, the cells were incubated with TPT for 24 h before
PI staining and flow cytometry to detect cell apoptosis.
Figure 5c-d shows that treating with TPT for the same
amount of time leads to cells with lower expression of
RARα and higher apoptosis percentages than in normal
cells. From the comparisons between the control group
and RARα-knockdown group, we concluded that low
levels of RARα proteins are beneficial for TPT-induced
apoptosis.
To determine whether RARα influences TPT-induced
apoptosis through the DNA damage signaling pathway,
we examined the related protein γ-H2AX. Increasing
phosphorylation of H2AX was observed in Western
blots for cells with low RARα expression in the combin-
ation therapy group (Fig. 5e). To further confirm the
role of RARα in DNA damage, lentivirus transduction
was used to overexpress RARα in HL60 cells. Figure 5f
shows that the increasing phosphorylation of H2AX was
reversed in the RARα-overexpression group, and this
observation demonstrated that the downregulation of
RARα may be a key factor for the accumulation of DNA
damage and apoptosis.
Synergistic antitumor efficacy of TPT and ATRA in HL60
xenografts
In light of the in vitro synergistic effect of TPT and
ATRA, we studied the in vivo anticancer activity of the
combination therapy in nude mice bearing HL60 xeno-
grafts as described in the Materials and Methods.
Fig. 4 ATRA synergistically induced DNA damage in combination with TPT. a and b HL60 cells were treated with or without 40 nM TPT or 1 μM
ATRA for 1 h. Alkaline comet assay was used for detection of single-strand breaks (SSBs). Representative comet images of each group were shown
and 200nM TPT served as the positive control (magnification 200×). Tail Moment and Tail DNA% were analysised the data from Comet assay. Each
point represents mean ± SD of three independent experiments. *Significantly different (P < 0.05) from the control, according to the Dunnett’s test.
c and d AML cells were exposed to TPT (40 nM), ATRA (1 μM), or in combination for indicated times, after that protein extracts were immunoblotted
with specific antibodies of γ-H2AX (c), p-Chk1/2, Chk1/2 (d)
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Figure 6a shows that the i.p. administration of ATRA
at a dose of 5 mg/kg twice per week for nine days pro-
duced no significant difference in the mean RTV
compared to the control group (mean RTV, ATRA vs.
control: 12.5 vs. 17.1; P > 0.05). However, after a dosage
of 2 mg/kg every week for nine days, TPT exerted a
Fig. 5 RARα participated in synergistic induction of apoptosis by TPT and ATRA treatment. a After incubation with TPT (40 nM), ATRA (1 μM), or
combination for 24 h, the lysates of HL60 cells were prepared for western blot analysis of RARα expression. b. HL60 cells were transfected by
negative control (NC) or shRNA of RARα. Western blot analysis showed decreased RARα protein levels in both cell lines. c and d After infection of
72 h, cells were treated with TPT for 24 h. The apoptosis ratio of HL60 cells were detected by flow cytometry. *: Compared to TPT group, p < 0.05.
The experiments were performed three times independently, and the error bars represent the SD around the mean. e After transfection of NC or
siRNA of RARα, HL60 cells were treated with TPT for indicated minutes. Protein expression of γ-H2AX was analyzed by western blot and densitometry
quantification based on α-tublin expression. f After transfection of vector or RARα plasmid, HL60 cells were treated with TPT for indicated minutes and
protein expression of γ-H2AX was analyzed by western blot
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moderate tumor growth inhibitory effect (mean RTV,
TPT vs. control: 10.4 vs. 17.1; P < 0.05). As predicted,
TPT plus ATRA caused marked tumor growth inhib-
ition (T/C value: 33.3 %) that was significantly greater
than TPT (T/C value: 60.8 %) or ATRA treatment
alone (T/C value: 73.1 %; mean RTV, combination vs.
TPT: 5.7 vs.10.4; P < 0.01). Furthermore, compared to
the initial body weights, combination treated mice
showed no significant body weight loss in Fig. 6b.
The TUNEL assay was performed to evaluate the
apoptosis-inducing abilities of the TPT and/or ATRA
treatments. As shown in Fig. 6c, the number of TUNEL-
positive cells was significantly increased in the tumor tis-
sues of combination-treated mice. All in vivo data were
consistent with previous in vitro data and further sup-
ported that the synergistic antitumor efficacy of TPT
and ATRA was a result of TPT aroused apoptosis.
Discussion
Acute myeloid leukemia is most often diagnosed in older
people and children; more than 50 % of patients with
AML are over-60 and 15-20 % are under 16 years old
[33, 34]. Chemotherapy is the only treatment option for
the majority of AML patients and the most frequently
used drugs are the deoxycytidine analog cytarabine and
an anthoursacycline antibiotic, such as daunorubicin,
idarubicin and the anthoursacenedione mitoxantrone
[3]. However, multiple chemotherapy treatments are in-
tolerable for children and older people with AML, there-
fore, new effective therapies with fewer side effects are
urgently needed. In this study, we demonstrated that
ATRA had a synergistic cytotoxicity with TPT for AML
in vitro and in vivo closely related to DNA damage-
induced apoptosis via RARa activity inhibition.
ATRA used in combination with chemotherapy has
been shown to improve the outcome of patients with
breast cancer, lung cancer, ovarian cancer and gastric
cancer, and only presents a few side effects, which sug-
gests a potential for clinical application in AML [35, 36].
Previous studies in ovarian, gastric and melanoma cancer
cells have shown that retinoic acid has synergistic effects
on DNA damage with the drug cisplatin [37]. TPT is ef-
fective alone with cytotoxicity effects less than the doxo-
rubicin (a classical AML drug) group (Additional file 1:
Figure S1) or when combined with other drugs for AML,
such as lapatinib, paclitaxel. However, TPT is limited by
its toxicity [14, 16, 17]. ATRA was proposed as a potential
drug to enhance the anticancer activity of TPT. We dem-
onstrated that ATRA decreases the concentration that
causes DNA damage from 200 nM to 40 nM TPT.
DNA integrity is critical for proper cellular function
and proliferation in AML. Once a DNA lesion occurs, it
leads to replication-associated DNA double-strand
breaks (DSBs) that eventually cause apoptosis if the
damaged DNA cannot be properly repaired [38]. Tar-
geted therapies designed to induce apoptosis in leukemic
cells are currently the most promising antileukemia
strategies. We used flow cytometry analysis with PI
staining, morphological evidence of apoptotic bodies,
and immunoblotting to determine if the ratio of growth
inhibition was induced by caspase-mediated apoptosis.
The comet assay revealed that treatment with TPT and
ATRA for one hour induces DNA SSBs in HL60 cells at
high concentrations of TPT, although neither 40 nM
Fig. 6 Efficacy of TPT combined with ATRA treatment regimen in vivo. Mice transplanted with HL60 human xenografts were randomly divided
into 4 groups and given injection of TPT (2 mg/kg, i.p.), ATRA (5 mg/kg, i.g.), combination, or vehicle for a period of 9 days. a Relative tumor
volume was expressed as mean ± SD (n = 3 per group). b The average body weight of each group was expressed as mean ± SD (n = 3 per group).
c Representative fluorescence images of TUNEL staining of tumor tissues collected from each group (magnification 100x)
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TPT or 1 μM ATRA caused the SSBs first when using
ATRA combined with TPT for one hour. Moreover, the
DNA damage pathway and its transducers (Chk1, Chk2)
were activated by TPT and ATRA at higher rates than
TPT. Over time, the SSBs became DSBs and finally led
to cell death by apoptosis.
ATRA binds to the retinoic acid receptor (RAR), RAR-
alpha, RAR-beta, and RAR-gamma, which is bound to
DNA as a heterodimer with the retinoid X receptor
(RXR) in regions called retinoic acid response elements
(RAREs), from there it affects gene transcription and
modulates a wide variety of biological processes, such as
apoptosis [31]. In our study, RARα was knocked-down
and the cells were susceptible to TPT, which increased
the apoptosis rate. Therefore, we concluded that the ex-
istence of RARα was unfavorable for programmed cell
death. The combination regime showed that ATRA
downregulates the protein level of RARα, and this might
be the key for synergistic effects in this anticancer ther-
apy. As a result, DNA damage can be induced more eas-
ily with ATRA. However, the influence of RARα on
TPT-induced DNA damage has not been explained, and
the role of ATRA in the DNA damage pathway needs
further exploration.
Conclusion
In summary, the combination of TPT and ATRA exhib-
ited synergistic antitumor activity in vitro and in vivo
demonstrated by a decreased tumor cell survival fraction,
increased inhibition of tumor cell proliferation, significant
activation of apoptosis cascades and an increased tumor
growth inhibitory rate. Moreover, the synergistic activity
was related to the suppression of RARα proteins and
caused single-strand DNA breaks, ultimately leading to
cell death by generating double-stranded DNA breaks
during DNA replication. Our results indicate that the
combination therapy is a promising alternative to chemo-
therapeutic treatment for AML and should be further
tested in clinical trials.
Additional file
Additional file 1: Figure S1. The TPT effect compared with doxorubicin
(ADR). TPT induced cytotoxicity was Compared with ADR in AML cells. 4 ×
103 cells per well were cultured in 96-well plates and incubated with the
indicated concentrations of TPT and ADR for 48 h. Mean ± SD from three
independent experiments. (TIF 10371 kb)
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